Cargando…
Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity
This editorial discusses flaws in the current system for reporting adverse events.
Autor principal: | Sartor, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759825/ https://www.ncbi.nlm.nih.gov/pubmed/29158364 http://dx.doi.org/10.1634/theoncologist.2017-0437 |
Ejemplares similares
-
Three aspects of acupuncture-related adverse events: Issues around the reporting of acupuncture-related adverse events
por: Kim, Tae-Hun, et al.
Publicado: (2023) -
How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine
por: Shakir, Saad, et al.
Publicado: (2020) -
Reporting adverse drug events to the Therapeutic Goods Administration
por: Martin, Jennifer H, et al.
Publicado: (2021) -
Conflicts of Interest, Baselga, and Clinical Trialists
por: Sartor, Oliver
Publicado: (2018) -
Response to “Evaluating Adverse Events in Databases”
por: Calapai, Fabrizio, et al.
Publicado: (2023)